MC Sciences is a seed-funded pre-clinical stage company developing the Next Generation Mast Cell Therapeutics targeting a diseases in immunology, inflammation, gastroenterology and dermatology.

Based on our significant drug development progress with our seed investment that exceeds industry best practice, we are preparing for a Series A investment with strong partners by the second half of the year 2024 with a clear defined timeline. Clear target of the Series A investment is to rapidly advance our Lead Program to the clinical phase – including first clinical phase readouts in clearly defined disease indications with high unmet need and significant market potential.

Should you be interested to participate in the Series A for MC Sciences, we welcome to you get in touch and look forward to getting to know your interest.